Dr. Reddys Laboratories is currently trading at Rs. 3092.00, up by 5.80 points or 0.19 % from its previous closing of Rs. 3086.20 on the BSE.
The scrip opened at Rs. 3095.00 and has touched a high and low of Rs. 3108.20 and Rs. 3083.05 respectively. So far 4072 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.
Last one week high and low of the scrip stood at Rs. 3182.80 and Rs. 3048.05 respectively. The current market cap of the company is Rs. 52743.66 crore.
The promoters holding in the company stood at 25.58%, while Institutions and Non-Institutions held 42.02% and 32.40% respectively.
Dr. Reddy’s Laboratories has entered into a definitive agreement with Teva Pharmaceutical Industries (Teva) and an affiliate of Allergan plc to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan’s generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics transaction and approval by the US Federal Trade Commission of Dr. Reddy’s as a buyer.
The portfolio being acquired is a mix of filed ANDAs pending approval and an approved ANDA, and comprised of complex generic products across diverse dosage forms. According to IMS Health, the combined sales of the branded versions of the products in the US are approximately $3.5 billion MAT for the most recent twelve months ending in April 2016.
Dr. Reddy’s Laboratories is acquiring the portfolio on a cash-free, debt-free basis and expects to finance the transaction using a combination of cash on hand and available borrowings under existing credit facilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1486.55 |
| Dr. Reddys Lab | 5860.25 |
| Cipla | 1482.55 |
| Zydus Lifesciences | 1072.35 |
| Lupin | 1613.65 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
